Alnylam Pharmaceuticals, Inc. (ALNY) key performance indicators and operating metrics (19 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Cost of Goods Sold as a Percentage of Net Product Revenues | 20.00 percent | FY2026-Q1 |
| AMVUTTRA Net Product Revenues | 890M | FY2026-Q1 |
| GIVLAARI Net Product Revenues | 74M | FY2026-Q1 |
| Non-GAAP Net Income per Common Share (Diluted) | 2.05 USD_per_share | FY2026-Q1 |
| ONPATTRO Net Product Revenues | 20M | FY2026-Q1 |
| OXLUMO Net Product Revenues | 51M | FY2026-Q1 |
| Non-GAAP Net Income per Common Share (Basic) | 1.99 USD_per_share | FY2026-Q1 |
| Total Net Product Revenues | 1.04B | FY2026-Q1 |
| Total Rare Net Product Revenues | 126M | FY2026-Q1 |
| Non-GAAP Net Income | 273.04M | FY2026-Q1 |
| Non-GAAP Income from Operations | 338.79M | FY2026-Q1 |
| Combined Net Product Revenues | 995M | FY2025-Q4 |
| TOTAL Rare (YoY % Growth) | 26.00 percent | FY2025-Q4 |
| GAAP Income (Loss) from Operations | 131.72M | FY2025-Q4 |
Back to ALNY overview · ALNY earnings · ALNY holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.